Tony Berberabe, MPH

Abiraterone/prednisone plus olaparib improves survival outcomes vs monotherapy or sequential use in BRCA1/2- or ATM-altered mCRPC.

Phase 3 LITESPARK-011 trial results demonstrated PFS and ORR benefits with belzutifan plus lenvatinib vs cabozantinib in advanced ccRCC after ICI therapy.

Neoadjuvant EV plus pembrolizumab significantly improved event-free survival and overall survival vs gemcitabine/cisplatin in the phase 3 KEYNOTE-B15 trial.

Atezolizumab plus chemotherapy reduced risk of death or recurrence by 50% compared with chemotherapy alone for patients with stage III dMMR colon cancer.

Adding panitumumab to neoadjuvant FOLFOX cut recurrence risk and improved survival in locally advanced, RAS/BRAF wild-type colon cancer.

The combo showed safety and efficacy in patients with c-MET protein overexpression who progressed on prior osimertinib.

Treatment with pirtobrutinib induced superior progression-free survival among heavily pretreated patients with relapsed or refractory CLL/SS previously treated with a covalent BTK inhibitor.

Patients with metastatic castration-resistant prostate cancer who received radium-223 prior to docetaxel had better quality of life and tolerability scores than those who received docetaxel first.

The administration of CAR T-cell therapy in an outpatient setting was deemed feasible and safe for patients with relapsed/refractory non-Hodgkin lymphoma.

Data from the phase 3 EMERALD trial showed that elacestrant’s benefit was consistent across various subgroups.

Phase 3 findings from the CLL12 trial support a watch-and-wait approach over systemic treatment with ibrutinib for patients with asymptomatic early-stage chronic lymphocytic leukemia.

Pembrolizumab inspired a 70% risk reduction in women with mismatch repair–deficient advanced endometrial cancer and a 46% risk reduction in patients with mismatch repair–proficient disease.

Findings from the phase 3 SUNLIGHT study showed that adding bevacizumab to trifluridine/tipiracil boosted overall survival in metastatic colorectal cancer.

Investigators reported that mitomycin gel was not associated with decrements in urinary symptoms, bloating and flatulence, or malaise, and that sexual function only mildly worsened.

The CD40 agonist sotigalimab in combination with pembrolizumab yielded promising outcomes in patients with unresectable stage III or IV metastatic melanoma.

While survival rates in T-cell acute lymphoblastic leukemia remain around 90%, researchers are optimistic that the use of targeted therapies and immunotherapies will continue to improve treatment options.

Treating patients with relapsed/refractory multiple myeloma with Talquetamab at RP2D elicits high clinical response rate.

Pediatric precision oncology in a real-world, multinational setting is feasible. For the subgroup of children with very high priority level targets, the INFORM registry provided therapeutic opportunities and new diagnostic information.

For men with positive needle biopsy for prostate cancer, active surveillance (AS) did not negatively impact their quality-of-life compared with men who had a negative prostate needle biopsy.

Although use of robotic surgery for prostate cancer has surpassed open surgical procedures, the impact of this approach on patient quality of life has not been well-studied.

When the United States Preventive Services Task Force (USPSTF) recommended against routine PSA screening for early detection of prostate cancer in May 2012, it caused a sea change in practice patterns among primary care physicians.

A new study has found that older, single white males with advanced bladder cancer have the highest suicide risk among those with other cancers of the male genitals and urinary system.

The continuing contentious debate about screening for prostate cancer remains top of mind among the public and lay press, but, Leonard G. Gomella, MD, told attendees at the 8th International Prostate Cancer Congress, the decision to screen or not to screen boiled down to "using common sense, shared decision making, and choosing the right patients to screen."

The first iteration of the American Society of Clinical Oncology's (ASCO's) endeavor to capture and harness big data, CancerLinQ, is scheduled for release in late 2015.

In May 2014, ASCO issued guidelines recommending the administration of adjuvant tamoxifen for 10 years in women with stage I-III hormone receptor (HR)-positive breast cancer, based on data from the collection of 5 clinical trials.

Even though breast cancer predominantly affects white women, breast cancer outcomes are worse among black women. But a new study suggests that enrollment in a federal program may help reduce racial disparities among these patients.

Does Medicare coverage for patients with cancer match up to what they actually want covered?

As the use of electronic patient portals grows, a new study examines the use of these portals by cancer patients, extending the doctor-patient relationship to new boundaries.

A pilot program initiated by UnitedHealthcare involving 5 oncology groups that focused on best treatment practices and health outcomes, rather than the number of drugs that oncologists prescribe, resulted in a 34% reduction in medical costs.

Patients with advanced cancer who received early specialized palliative care reported better quality of life and satisfaction, according to results from a randomized trial comparing such services with usual care published in The Lancet.